The remarkable success of anti‐CD20 B cell depletion therapies in reducing the burden of
multiple sclerosis (MS) disease has prompted significant interest in how B cells contribute to …

Multiple sclerosis (MS) is characterized by peripheral and central inflammatory features, as
well as demyelination and neurodegeneration. The available Food and Drug Administration …

Background and Objectives Antibodies to CD20 efficiently reduce new relapses in multiple
sclerosis (MS), and ocrelizumab has been shown to be effective also in primary progressive …

Background Anti-CD20 is a highly effective therapy for multiple sclerosis (MS), a disease
with multiple abnormalities in function of B and T cells and innate immune cells. Anti-CD20 …

The success of selective B-cells depleting therapies, as the anti-CD20 antibodies, in patients
with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune …

B cells fulfill multifaceted functions that influence immune responses during health and
disease. In autoimmune diseases, such as inflammatory bowel disease, multiple sclerosis …

Multiple sclerosis (MS) is characterized by a compromised blood-brain barrier (BBB)
resulting in central nervous system (CNS) entry of peripheral lymphocytes, including T cells …

Background and Objectives The B cell–depleting anti-CD20 antibody ocrelizumab (OCR)
effectively reduces MS disease activity and slows disability progression. Given the role of B …

Ofatumumab is the first, fully human, anti-CD20 monoclonal antibody in Phase 3
development for multiple sclerosis (MS). The study focused on changes in lymphocyte …

B cells are a critical arm of the adaptive immune system. After encounter with antigen, B cells
are activated and differentiate into plasmablasts (PBs) and plasma cells (PCs). Although …